Results 51 to 60 of about 6,040 (212)
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs
Pharmaceuticals, 2010 Several studies have shown that blood pressure can be lowered by the use of drugs that are not traditional antihypertensive drugs. This might be of clinical importance when many risk patients are treated by combination drug therapy in order to prevent ...
Peter M. Nilsson, Renata Cifkova
doaj +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus +7 more
wiley +1 more source
Rimonabant, Gastrointestinal Motility and Obesity [PDF]
Current Neuropharmacology, 2012 Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects ...
Sun, Yan, Chen, Jiande
openaire +2 more sources
Rimonabant-induced catatonia in schizophrenia: A case report
, 2009 Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease.
Sivakumar, Palanimuthu T. +7 more
core +1 more source
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source
Biomolecules, 2020 Obesity rates are increasing worldwide and there is a need for novel therapeutic treatment options. The endocannabinoid system has been linked to homeostatic processes, including metabolism, food intake, and the regulation of body weight.
Thomas Murphy, Bernard Le Foll
doaj +1 more source
Rimonabant—Ein Cannabinoid-Rezeptor-Antagonist zur Gewichtsreduktion und Rauchentwöhnung
, 2005 Treatment of lifestyle risk factors such as and smoking is difficult. These risk factors play important roles in cardiovascular disease. Current therapeutic strategies only have minor impact on associated metabolic changes such as low HDL cholesterol and
Roberto Corti +3 more
core +1 more source
Brain and Behavior, Volume 16, Issue 5, May 2026.This study explored the association between the FAAH rs324420 polymorphism and substance use disorders in individuals with methamphetamine, opioid, and combined use. The rs324420 CA genotype was linked to a reduced risk of substance use disorder, while higher craving scores were observed in individuals with combined opioid–methamphetamine use. ABSTRACT
Özlem Erekli‐Arat +4 more
wiley +1 more source
The role of cannabinoid receptor 1 in the development of oxidative/nitrosative stress in mice with non-alcoholic fatty liver disease [PDF]
Medicinski Podmladak, 2019 Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is hepatic manifestation of metabolic syndrome. It represents a spectrum of diseases ranging from steatosis, non-alcoholic steatohepatitis (NASH), that may progress to fibrosis, cirrhosis and ...
Brkić Dušan, Jorgačević Bojan
doaj